Home › Companies › 4D Molecular Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and 4D Molecular Therapeutics, Inc.’s Form 8-K, filed June 22, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of June 17, 2026: 5 items on 4D Molecular Therapeutics, Inc.’s Form 8-K, filed June 22, 2026: 2 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore 4D Molecular Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are 4D Molecular Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 22, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Nancy Miller-Rich | 35,880,028 | -- | -- | 1,193,202 | 6,964,792 | 97% | Not verified | — |
| Elect Director: John F. Milligan, Ph.D. | 35,778,121 | -- | -- | 1,295,109 | 6,964,792 | 97% | Not verified | — |
| Elect Director: Shawn Cline Tomasello, MBA | 30,508,706 | -- | -- | 6,564,524 | 6,964,792 | 82% | Not verified | — |
| 2. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 | 43,900,362 | 55,763 | 81,897 | -- | -- | 99.8% | Approved | — |
| 3. On an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement | 36,065,437 | 940,414 | 67,379 | -- | 6,964,792 | 97% | Approved | — |
Source: 4D Molecular Therapeutics, Inc., Form 8-K, filed with the SEC on June 22, 2026 — read the filing on EDGAR.
Each item below shows how the 166 asset managers that disclosed a 4D Molecular Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: John F. Milligan, Ph.D.
4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: John F. Milligan, Ph.D.”): 35,778,121 for, 1,295,109 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 10,184,251 for, 265,584 withheld, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,760,672 | 0 | 3 | 5,624 | For |
| State Street | 1,540,682 | 0 | 0 | 1,890 | For |
| BlackRock | 1,538,756 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 843,240 | 0 | 0 | 0 | For |
| Federated Hermes | 715,363 | 0 | 0 | 0 | For |
| Fidelity | 713,535 | 0 | 0 | 0 | For |
| TIAA | 548,991 | 0 | 0 | 0 | For |
| Charles Schwab | 328,732 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 200,177 | Withhold |
| Bridge Builder Trust | 198,386 | 0 | 0 | 0 | For |
| Northern Trust | 179,773 | 0 | 0 | 0 | For |
| Voya | 109,431 | 0 | 0 | 0 | For |
| American Century | 107,264 | 0 | 0 | 0 | For |
| Equitable | 69,943 | 0 | 0 | 36,890 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 61,699 | 0 | 0 | 0 | For |
| JPMorgan | 57,027 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 50,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 40,739 | 0 | 0 | 4,816 | Mixed |
| ProShares | 39,478 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 37,875 | 0 | 0 | 0 | For |
| SEI | 30,779 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 21,946 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 21,599 | 0 | 0 | 0 | For |
| T. Rowe Price | 19,733 | 0 | 0 | 0 | For |
| Global X | 18,995 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Nancy Miller-Rich
4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Nancy Miller-Rich”): 35,880,028 for, 1,193,202 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 10,182,757 for, 267,078 withheld, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,762,533 | 0 | 3 | 3,763 | For |
| State Street | 1,540,682 | 0 | 0 | 1,890 | For |
| BlackRock | 1,538,756 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 843,240 | 0 | 0 | 0 | For |
| Federated Hermes | 715,363 | 0 | 0 | 0 | For |
| Fidelity | 713,535 | 0 | 0 | 0 | For |
| TIAA | 548,991 | 0 | 0 | 0 | For |
| Charles Schwab | 328,732 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 200,177 | Withhold |
| Bridge Builder Trust | 198,386 | 0 | 0 | 0 | For |
| Northern Trust | 179,773 | 0 | 0 | 0 | For |
| Voya | 109,431 | 0 | 0 | 0 | For |
| American Century | 107,264 | 0 | 0 | 0 | For |
| Equitable | 69,943 | 0 | 0 | 36,890 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 61,699 | 0 | 0 | 0 | For |
| JPMorgan | 57,027 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 50,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 40,739 | 0 | 0 | 4,816 | Mixed |
| ProShares | 39,478 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 37,875 | 0 | 0 | 0 | For |
| SEI | 30,779 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 21,946 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 21,599 | 0 | 0 | 0 | For |
| T. Rowe Price | 19,733 | 0 | 0 | 0 | For |
| Global X | 18,995 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: Election of three Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Shawn Cline Tomasello, MBA
4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Shawn Cline Tomasello, MBA”): 30,508,706 for, 6,564,524 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 7,925,996 for, 2,523,825 withheld, 17 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,760,658 | 0 | 17 | 5,624 | For |
| State Street | 1,241 | 0 | 0 | 1,541,331 | Withhold |
| BlackRock | 1,538,756 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 843,240 | 0 | 0 | 0 | For |
| Federated Hermes | 715,363 | 0 | 0 | 0 | For |
| Fidelity | 713,535 | 0 | 0 | 0 | For |
| TIAA | 548,991 | 0 | 0 | 0 | For |
| Charles Schwab | 328,732 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 200,177 | Withhold |
| Bridge Builder Trust | 147,330 | 0 | 0 | 51,056 | Mixed |
| Northern Trust | 0 | 0 | 0 | 179,773 | Withhold |
| Voya | 0 | 0 | 0 | 109,431 | Withhold |
| American Century | 0 | 0 | 0 | 107,264 | Withhold |
| Equitable | 69,943 | 0 | 0 | 36,890 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 61,699 | 0 | 0 | 0 | For |
| JPMorgan | 57,027 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 50,000 | Withhold |
| Lincoln Financial | 12,539 | 0 | 0 | 33,016 | Mixed |
| ProShares | 0 | 0 | 0 | 39,478 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 37,875 | Withhold |
| SEI | 30,779 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 0 | 0 | 21,946 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 21,599 | Withhold |
| T. Rowe Price | 19,733 | 0 | 0 | 0 | For |
| Global X | 18,995 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Combines 10 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: Approval, on an advisory, non- binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote").
4D Molecular Therapeutics, Inc.’s own tally for this item (“3. On an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement”): 36,065,437 for, 940,414 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,766,297 | 2 | 0 | 0 | For |
| State Street | 1,541,901 | 671 | 0 | 0 | For |
| BlackRock | 1,538,756 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 843,240 | 0 | 0 | 0 | For |
| Federated Hermes | 715,363 | 0 | 0 | 0 | For |
| Fidelity | 713,535 | 0 | 0 | 0 | For |
| TIAA | 548,991 | 0 | 0 | 0 | For |
| Charles Schwab | 328,732 | 0 | 0 | 0 | For |
| Dimensional | 200,177 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 198,386 | 0 | 0 | 0 | For |
| Northern Trust | 179,773 | 0 | 0 | 0 | For |
| Voya | 109,431 | 0 | 0 | 0 | For |
| American Century | 0 | 107,264 | 0 | 0 | Against |
| Equitable | 106,833 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,699 | 0 | 0 | 0 | For |
| JPMorgan | 57,027 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 50,000 | 0 | 0 | Against |
| Lincoln Financial | 45,555 | 0 | 0 | 0 | For |
| ProShares | 39,478 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 37,875 | 0 | 0 | 0 | For |
| SEI | 30,779 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 21,946 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 21,599 | 0 | 0 | 0 | For |
| T. Rowe Price | 19,733 | 0 | 0 | 0 | For |
| Global X | 18,995 | 0 | 0 | 0 | For |
Fund voting reports, all 49 managers: 10,288,998 for, 160,840 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 6,980,400 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 4,619,802 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 3,270,000 | 0 | 0 | 0 | For |
| BVF INC/IL | 2,879,289 | 0 | 0 | 0 | For |
| BlackRock | 1,497,286 | 30,453 | 0 | 0 | For |
| Goldman Sachs | 1,243,984 | 0 | 0 | 0 | For |
| Evergreen Quality Fund GP, Ltd. | 951,474 | 0 | 0 | 0 | For |
| Federated Hermes | 890,889 | 13,288 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 858,456 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 820,973 | 0 | 0 | 0 | For |
| State Street | 727,837 | 3,017 | 0 | 0 | For |
| Nuveen | 564,621 | 0 | 0 | 0 | For |
| ACUTA CAPITAL PARTNERS, LLC | 507,801 | 0 | 0 | 0 | For |
| Trails Edge Capital Partners, LP | 453,014 | 0 | 0 | 0 | For |
| Charles Schwab | 328,782 | 0 | 0 | 0 | For |
| Vanguard | 299,322 | 0 | 0 | 0 | For |
| Northern Trust | 256,087 | 2,296 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 202,864 | 0 | 0 | 0 | For |
| Woodline Partners LP | 200,000 | 0 | 0 | 0 | For |
| Catalio Capital Management, LP | 183,867 | 0 | 0 | 0 | For |
| Voya | 158,443 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 146,592 | 0 | 0 | 0 | For |
| Renaissance | 142,703 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 140,964 | 0 | 0 | 0 | For |
| Peapod Lane Capital LLC | 136,865 | 0 | 0 | 0 | For |
Institutional-manager reports, all 132 managers: 30,061,206 for, 289,280 against, 107 not voted. Showing the 25 largest; see all in the interactive database.
99.8% Approved · of votes cast
Description as filed by funds: Ratification of the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.
4D Molecular Therapeutics, Inc.’s own tally for this item (“2. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026”): 43,900,362 for, 55,763 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 10,449,779 for, 59 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,766,299 | 0 | 0 | 0 | For |
| State Street | 1,542,513 | 59 | 0 | 0 | For |
| BlackRock | 1,538,756 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 843,240 | 0 | 0 | 0 | For |
| Federated Hermes | 715,363 | 0 | 0 | 0 | For |
| Fidelity | 713,535 | 0 | 0 | 0 | For |
| TIAA | 548,991 | 0 | 0 | 0 | For |
| Charles Schwab | 328,732 | 0 | 0 | 0 | For |
| Dimensional | 200,177 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 198,386 | 0 | 0 | 0 | For |
| Northern Trust | 179,773 | 0 | 0 | 0 | For |
| Voya | 109,431 | 0 | 0 | 0 | For |
| American Century | 107,264 | 0 | 0 | 0 | For |
| Equitable | 106,833 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,699 | 0 | 0 | 0 | For |
| JPMorgan | 57,027 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 50,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 45,555 | 0 | 0 | 0 | For |
| ProShares | 39,478 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 37,875 | 0 | 0 | 0 | For |
| SEI | 30,779 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 21,946 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 21,599 | 0 | 0 | 0 | For |
| T. Rowe Price | 19,733 | 0 | 0 | 0 | For |
| Global X | 18,995 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 52,271,648 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.29% |
| 2 | State Street | 2.95% |
| 3 | BlackRock | 2.94% |
| 4 | JANUS INVESTMENT FUND | 1.61% |
| 5 | Federated Hermes | 1.37% |
| 6 | Fidelity | 1.37% |
| 7 | TIAA | 1.05% |
| 8 | Charles Schwab | 0.63% |
| 9 | Dimensional | 0.38% |
| 10 | Bridge Builder Trust | 0.38% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 13.35% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 8.84% |
| 3 | Novo Holdings A/S | 6.26% |
| 4 | BVF INC/IL | 5.51% |
| 5 | BlackRock | 2.92% |
| 6 | Goldman Sachs | 2.38% |
| 7 | Evergreen Quality Fund GP, Ltd. | 1.82% |
| 8 | Federated Hermes | 1.73% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.64% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.57% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BVF PARTNERS L P/IL | 10.23% | 13G |
| JANUS HENDERSON GROUP PLC | 10.04% | 13G |
| Goldman Sachs | 8.05% | 13F |
| BlackRock | 7.93% | 13F |
| Novo Holdings A/S | 6.98% | 13G |
| Vanguard Group | 5.92% | 13F |
| Biotechnology Value Fund, L.P. | 5.51% | DEF14A |
| State Street | 5.18% | 13F |
| David Kirn, M.D. | 3.17% | DEF14A |
| Geode Capital | 2.04% | 13F |
Percentages above are of 52,271,648 shares outstanding, as reported by 4D Molecular Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 4D Molecular Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At 4D Molecular Therapeutics, Inc.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 166 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,040 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory, non- binding basis, of the compensation of the Company's named… — 4D Molecular Therapeutics, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: 4D Molecular Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 22, 2026.
4D Molecular Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.